This retrospective cohort study used deidentified electronic health records (EHR) data linked with administrative claims from the Optum Labs Data Warehouse.
This retrospective cohort study used deidentified electronic health records (EHR) data linked with administrative claims from the Optum Labs Data Warehouse.
This systematic review and meta-analysis aims to address the literature gap and public health implications of ONP use.
No summary available
"Research shows that limiting access to lethal means is one of the most promising approaches to save lives. It can involve erecting barriers on buildings and bridges to prevent people from jumping, as well as decreasing the number of pills someone can buy or be prescribed at once. And reducing access to guns."
Further longitudinal studies and randomized clinical trials to evaluate the efficacy of interventions to reduce CU and CUD are needed.
Future research must prioritize integrated treatment platforms, implementation science to scale effective interventions like CM, and personalized strategies informed by genetics and neuroimaging.
This study demonstrated that intranasal naloxone was feasible, safe, and comparable to intravenous administration for the management of opioid poisoning in young children.
SUD status, AUD, and OUD in particular, warrant explicit incorporation into short-term risk stratification for respiratory infections in both routine clinical care and pandemic preparedness planning.
This study of recently admitted patients on methadone who also used cocaine examines their experiences and views on drug use and treatment.
These findings suggest UDT complements existing drug surveillance and provides unique insights into emerging fentanyl adulterants.
This study describes the availability of Medicare-enrolled OTPs in rural and urban counties.
These results can inform ongoing debates about the strengths and weaknesses of virtual-only OUD care.
No summary available
Evidence for sex-specific efficacy remains inconclusive.
In this meta-analysis, no medication demonstrated a significant benefit over placebo for abstinence.
In this cohort study, use of MAUDs was associated with improved survival among patients with severe ALD. This finding highlights the need for improved access to MAUDs among patients with severe ALD.
Findings provide implications for efforts aimed at discouraging vaping and suggest several possibilities for future work in the domain of narrative persuasion and social norm messaging.
These results support tightening alcohol use guidance in the United States, for both males and females, to no more than 1 drink per day.
NIH has cleared a first-in-human safety study of mitragynine, the primary alkaloid in kratom, to assess whether this opioid-receptor compound could be developed as a treatment for opioid use disorder. The move reflects both the promise seen in preclinical research and the central concern that kratom is itself psychoactive and potentially addictive, making safety and tolerability the immediate question.
The U.S. Drug Enforcement Administration opened a long-awaited administrative hearing June 29 on a proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, with proceedings expected to run into mid-July. A shift to Schedule III would formally recognize accepted medical use and ease research restrictions. AAPP supports the rescheduling of cannabis to enable the necessary research.
No summary available
Learn how wearable technology can enhance well-being, including prevention, treatment, and recovery for mental health and substance use.
The FDA has approved for eligible adults with early Alzheimer Disease to start lecanemab using weekly subcutaneous autoinjectors at home. The starting does is 500 mg weekly followed by 360 mg once weekly as maintenance.
A combination of THC and CBD eased symptoms in an especially frail population: patients with advanced dementia near the end of their lives.
Half as many young adults are misusing Adderall, Ritalin and other ADHD medications these days to help them remain alert at study or work, a new evidence review says. Misuse of ADHD stimulant meds among adults under 30 fell from 7.5% in 2016 to 3.7% in 2023, researchers report in the Journal of Clinical Psychopharmacology.